HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bile acid synthesis in the Smith-Lemli-Opitz syndrome: effects of dehydrocholesterols on cholesterol 7alpha-hydroxylase and 27-hydroxylase activities in rat liver.

Abstract
The Smith-Lemli-Opitz syndrome (SLOS) is a congenital birth defect syndrome caused by a deficiency of 3beta-hydroxysterol Delta(7)-reductase, the final enzyme in the cholesterol biosynthetic pathway. The patients have reduced plasma and tissue cholesterol concentrations with the accumulation of 7-dehydrocholesterol and 8-dehydrocholesterol. Bile acid synthesis is reduced and unnatural cholenoic and cholestenoic acids have been identified in some SLOS patients. To explore the mechanism of the abnormal bile acid production, the activities of key enzymes in classic and alternative bile acid biosynthetic pathways (microsomal cholesterol 7alpha-hydroxylase and mitochondrial sterol 27-hydroxylase) were measured in liver biopsy specimens from two mildly affected SLOS patients. The effects of 7- and 8-dehydrocholesterols on these two enzyme activities were studied by using liver from SLOS model rats that were treated with the Delta(7)-reductase inhibitor (BM15.766) for 4 months and were comparable with more severe SLOS phenotype in plasma and hepatic sterol compositions. In the SLOS patients, cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase were not defective. In BM15.766-treated rats, both enzyme activities were lower than those in control rats and they were competitively inhibited by 7- and 8-dehydrocholesterols. Rat microsomal cholesterol 7alpha-hydroxylase did not transform 7-dehydrocholesterol or 8-dehydrocholesterol into 7alpha-hydroxylated sterols. In contrast, rat mitochondrial sterol 27-hydroxylase catalyzed 27-hydroxylation of 7- and 8-dehydrocholesterols, which were partially converted to 3beta-hydroxycholestadienoic acids. Addition of microsomes to the mitochondrial 27-hydroxylase assay mixture reduced 27-hydroxydehydrocholesterol concentrations, which suggested that 27-hydroxydehydrocholesterols were further metabolized by microsomal enzymes. These results suggest that reduced normal bile acid production is characteristic of severe SLOS phenotype and is caused not only by depletion of hepatic cholesterol but also by competitive inhibition of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase activities by accumulated 7- and 8-dehydrocholesterols. Unnatural bile acids are synthesized mainly by the alternative pathway via mitochondrial sterol 27-hydroxylase in SLOS.
AuthorsA Honda, G Salen, S Shefer, A K Batta, M Honda, G Xu, G S Tint, Y Matsuzaki, J Shoda, N Tanaka
JournalJournal of lipid research (J Lipid Res) Vol. 40 Issue 8 Pg. 1520-8 (Aug 1999) ISSN: 0022-2275 [Print] United States
PMID10428990 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anticholesteremic Agents
  • Bile Acids and Salts
  • Cholestadienols
  • Dehydrocholesterols
  • Piperazines
  • cholesta-5,8-dien-3 beta-ol
  • BM 15766
  • Cytochrome P-450 Enzyme System
  • 7-dehydrocholesterol
  • Steroid Hydroxylases
  • Cholesterol 7-alpha-Hydroxylase
  • CYP27A1 protein, human
  • Cholestanetriol 26-Monooxygenase
Topics
  • Animals
  • Anticholesteremic Agents (pharmacology)
  • Bile Acids and Salts (biosynthesis)
  • Cholestadienols (pharmacology)
  • Cholestanetriol 26-Monooxygenase
  • Cholesterol 7-alpha-Hydroxylase (analysis)
  • Cytochrome P-450 Enzyme System (analysis)
  • Dehydrocholesterols (pharmacology)
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Liver (chemistry, drug effects)
  • Male
  • Microsomes, Liver (chemistry, drug effects, enzymology)
  • Mitochondria, Liver (chemistry, drug effects, enzymology)
  • Models, Biological
  • Models, Chemical
  • Piperazines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Smith-Lemli-Opitz Syndrome (classification, etiology, metabolism)
  • Steroid Hydroxylases (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: